169 results about "Herpes simplex disease" patented technology

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Hepatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses.

Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses.

Novel antiviral compounds of Formulae (I)-(III) are provided: (I) (II) (III) The inventive compounds, pharmaceutical compositions thereof, and kits including the inventive compounds are useful for the prevention and treatment of infectious diseases caused by viruses, for example, by Flaviviridae virus (e.g., Dengue virus (DENY)), Kunjin virus, Japanese encephalitis virus, vesicular stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus, Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses.

The present invention relates to a preparation method for a blattodea polypeptide substance, and a medical use of the blattodea polypeptide substance in anti-herpesvirus. Specifically the present invention relates to a blattodea extract effective fraction having a function of prevention and treatment of herpes simplex virus infection diseases, a preparation method and a medical use thereof. The Periplaneta Americana extract effective fraction of the present invention is a polypeptide substance with a molecular weight less than 5000 dalton, and is prepared by the following steps: carrying out extraction on fresh polypide or dried polypide of Periplaneta Americana with water or an organic solvent and a buffer, and then carrying out a membrane separation method to refine to obtain the product of the present invention, wherein the polypeptide active substance of the effective fraction has significant anti-herpes simplex virus (HSV-1 and HSV-2) activities, can be prepared into forms of a hydrogel, a cataplasm, lyophilized powder, a water agent, an aerosol, a suppository, a film agent, an external application liniment, and an ointment, and can be used for preparations of drugs for prevention and treatment of herpes simplex virus infections, daily chemical products or medical devices.

The invention provides a recombinant II type herpes simplex virus vector. An ICP34.5 gene and an ICP47 gene of a wild II type herpes simplex virus HG52 strain are removed in the virus vector, and preferably a human granulocyte macrophage-colony stimulating factor (hGM-CSF) expression box is inserted into the position where the ICP34.5 gene is removed. The invention also provides a preparation method of the recombinant II type herpes simplex virus vector, a recombinant virus using the recombinant II type herpes simplex virus as a vector, a medicinal composition consisting of the recombinant II type herpes simplex virus vector and a pharmaceutically acceptable vector or excipient, and application of the recombinant II type herpes simplex virus vector in preparation of a gene medicament for treating tumors. As the ICP34.5 gene is removed in the recombinant II type herpes simplex virus vector provided by the invention, the oncolysis virus is safe and can selectively grow and propagate in tumor cells; the ICP47 gene is removed to promote immune response and enhance oncolysis activity; and the curative effect of the recombinant II type herpes simplex virus vector is superior to that of the conventional recombinant I type herpes simplex virus vector, and the recombinant II type herpes simplex virus vector has high safety.

The invention relates to a method of treating neuronal apoptosis in a mammal using nucleic acid encoding HSV-2 ICP10PK, or a polypeptide encoded thereby. The invention further relates to a method of treating neuronal apoptosis in a mammal using ICP10PK in combination with a nucleic acid encoding bcl-2, or the polypeptide encoded thereby. The invention also relates to the use of ICP10PK and ICP10PK in combination with bcl-2 to treat non-neuronal diseases characterized by apoptosis.

The invention aims at providing a herpes virus type I PCR (polymerase chain reaction) fluorescence quantitative rapid test kit which can detect the specific nucleic acid sequence of pure herpes virus type I in a clinical sample and further achieve the purpose of rapidly judging the existence of the pure herpes virus type I. In order to realize the purpose, the technical scheme of the invention isas follows: the herpes virus type I PCR fluorescence quantitative rapid test kit provided by the invention comprises a DNA (deoxyribonucleic acid) extraction solution, a PCR reaction solution, a DNA polymerase, a positive quality control product, a weak positive quality control product, a negative quality control product and a quantitative reference product, wherein the PCR reaction solution comprises primers and a fluorescent probe, and the primers are divided into an upstream primer and a downstream primer. The herpes virus type I PCR fluorescence quantitative rapid test kit has the beneficial effect of filling in the blank of a fluorescence PCR kit for clinically detecting the pure herpes virus type I (HSV I) in China. Furthermore, a Taqman core technology platform and an arabidopsis thaliana internal control system are utilized for detecting the pure herpes virus type I (HSV I), so that the herpes virus type I PCR fluorescence quantitative rapid test kit has the advantages of highsensitivity, high specificity, stability, timeliness, convenience in operation and the like.

The invention discloses a notoginsenoside ST-4 which is a new dammarane type triterpenoid saponin compound shown in the structural formula (I), and a preparation method thereof. The invention also provides applications of the notoginsenoside ST-4 in the preparation of drugs against HSV-1. An HSV-1 strain and HELF (MRC-5) are used as cell experimental subjects to carry out the experiment of antiviral activity of the new compound which is the notoginsenoside ST-4. The results show that the notoginsenoside ST-4 has therapeutical effect for cells infected by HSV-1 and can reduce the infectivity of HSV-1 for MRC-5 cells and be applied to the preparation of drugs against HSV-1.

The present invention provides a herpes virus in which a non-essential gene for replication is inactivated More particularly, the present invention provides a herpes virus in which a non-essential gene for replication present in a UL or US region is inactivated. More preferably, the non-essential gene for replication contains US3 or UL56. The herpes virus may be preferably a herpes simplex virus, and more preferably herpes simplex virus 1 or herpes simplex virus 2. The present invention provides a method, composition and use for treating various diseases or disorders including tumor and infectious diseases. The present invention also provides a method, composition and use for activating a prodrug.

The invention relates to the technical field of detection of pathogenic microorganisms, in particular to a detection marker, primer probe pair, kit and detection method for herpesvirus hominis I typeand II type. By taking reverse repeated sequences RS1 and RS2 in an HSV genome as a target area, the detecting sensitivity can be further improved as two copies are available in the genome on the onehand and cross reactions are unlikely to be caused as the inter-nucleic acid similarity is low on the other hand.

The invention relates to an I, II herpes simplex virus fluorescence quantitative PCR detection method and kit thereof. Primers are designed direct towards DNA enzyme highly conservative region and then processed by PCR and a fluorescent probe is designed in the middle of the amplification sequence and then the annealing temperature of the reaction and the concentrations of the primers, the probe,the magnesium ion are optimized to establish the I, II herpes simplex virus real-time fluorescence PCR detection method. The kit ensures the sensitivity and accuracy and has features of simple and quick operation, reduced labor intensity of clinical detection, reduced cost of clinical PCR diagnosis, quick and simple performance of fluorescence quantitative PCR detection method. The method is usedfor quantitative detection of I, II herpes simplex virus with practical clinical application value.

The invention discloses a fluorescent polymerase chain reaction (PCR) kit for detecting herpes simplex virus type II, and belongs to the field of in-vitro diagnostic kit for nucleic acid. The kit comprises a positive reference, a negative reference, fluorescent polymerase chain reaction liquid, PCR primers and a specific fluorescent probe, polyethylene glycol (PEG) precipitation solution and lysis solution. The invention comprises a PCR system based on a fluorescent PCR technology, contains forward and reverse primers and the fluorescent probe for detecting the gene sequence of the herpes simplex virus type II, can detect the nucleotide sequence of the gene of the herpes simplex virus type II under proper PCR condition, can easily and quickly detect the infection of the HSV II in clinical samples and is high in specificity.

The invention provides recombined II-type herpes simplex virus. In the virus, ICP34.5 gene of a wild II-type herpes simplex virus HG52 strain is excluded, and a fluorescent protein expression box is inserted in the gene group. The invention also provides a preparation method of the recombined II-type herpes simplex virus, the application of the recombined II-type herpes simplex virus in preparation of the drug for diagnosing tumours, and a tumour diagnostic reagent kit with the recombined II-type herpes simplex virus. In the recombined II-type herpes simplex virus disclosed by the invention, the ICP34.5 gene is excluded, so that the recombined II-type herpes simplex virus can selectively grow and breed in tumour cells, the recombined II-type herpes simplex virus is inserted in the fluorescent protein expression box and can give out fluorescence in tumour cells, so that the tumour diagnostic reagent kit with the recombined II-type herpes simplex virus can quickly, accurately, sensitively and broadly detect whether a sample to be detected contains tumour cells or not.

The invention discloses a set of probes used for TORCH detection, and comprises a toxoplasma TOX probe which is shown in a SEQ ID NO. 1; a rubella virus RV probe which is shown in a SEQ ID NO.2; a cytomegalovirus CMV probe which is shown in a SEQ ID NO.3; a herpes simplex virus HSV I type probe which is shown in a SEQ ID NO.4; and a herpes simplex virus HSV II type probe which is shown in a SEQ ID NO.5. The invention also comprises a gene chip containing the probe and a kit thereof, visible light passing through a biochip can be amplified, signal resolution is high, and a signal can be shoot by a common digital camera or directly read by naked eyes. Compared with a traditional fluorescent label, the gene chip has good effect. Through specific primer and probe selection, by combining a gene chip technology, detection efficiency and accuracy degree are increased, and requirement of on-site detection for hospital and antenatal testing.

The invention provides methods and kits for immunizing animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2. The protective immune response elicited by the methods and kits of the invention is characterized by robust humoral, cellular, and mucosal immunity. In particular, the invention provides a heterologous immunization method comprising a priming DNA vaccine encoding an antigen and a boosting protein vaccine, in which the protein form of the antigen is encapsulated in liposomes. Methods of preventing primary acute, latent and recurrent viral infections, such as that caused by HSV-2 virus, and methods of providing passive protective immunity against a viral pathogen such as HSV-2 virus to a mammal are also disclosed.

The invention relates to a pharmaceutical composition with dammarane-type tetracyclic triterpene compound as an active component and an application thereof to the pharmaceutical field. Panax notoginseng is separated to obtain three dammarane-type tetracyclic triterpene compounds as shown in the following structural formula, in vitro pharmacological experiments show that the pharmaceutical composition has good in vitro inhibitory activity for herpes simplex virus type I and can be applied to the preparation of medicines for resisting herpes simplex virus type I and is used for treating herpetic keratitis, encephalitis, pneumonia, ulcerative stomatitis, blister and the like caused by herpes simplex virus type I.

A method of treating patients having viral infections including herpes simplex virus 1 and 2 infections and human papillomavirus infections by topically administering Product R, a peptide-nucleic acid preparation, by itself or in a composition comprising Product R and other pharmaceutically acceptable carriers for topical administration, is disclosed.

The present invention is directed oncolytic Herpes simplex-1 viruses whose replication is controlled using a tetracycline operator / repressor system. The invention also includes DNA sequences used in making the viruses and methods in which these viruses are used in the treatment of cancer patients with solid tumors.

Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42 AND UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

The invention discloses a protein chip for detecting pathogen antibodies of blood and cerebrospinal fluid and its preparing method, and the protein chip includes substrate and peculiar-culture or shape protein or polypeptide antigen of array distributed pathogen and contrasted dot coating, where the substrate is a glass substrate; and the antigen and contrasted dot coating refers to 13 antigens with ten indexes including HSV-I, HSV-II, VZV, CMV, EBV, RV, JEV, MV, MT and LP, uniformly distributed on the glass substrate in a dot matrix form, and positive contrast, negative contrast and blank contrast. The protein chip of the invention can obtain multiple-index reacting result only by one reaction, judges infection of different pathogens and has the characters of quickness, high efficiency, accuracy and parallel diagnosis.

The present invention relates to an application of pithecellobium clypearia extract in medicine and food. It adopts pithecellobium clypearia aqueous extract or ethyl alcohol extract as effective component and adds conventional medicinal auxiliary or food additive, and can make them into tablet, capsul, granule preparation, pills preparation and oral liquor preparation. Said pithecellobium clypearia extract has strong inhibition effect for influenza virus, parainfluenza virus, enteric virus, rhinovirus and mumps virus and has strong antioxidation activity.

The invention provides a rubiaceae-type cyclopeptide compound rubiyunnanin F(8), a pharmaceutical composition with the compound as an active component, as well as a preparation method and application of the compound. The invention provides the preparation method of the compound and application of the compound in preparation of anti-herpes simplex virus type I (HSV-1) medicines.